AKT1 and major depressive disorder: SGKL treatment improves the depression‐induced alteration of gut microbiota that stimulates the phosphorylation of the PI3K/Akt/mTOR pathway, which represses microglial activation through PI3K/Akt/mTOR pathway‐regulated inflammation in the hippocampus.